Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden

This study establishes (1) a threshold level for MRD above which prognosis is worse, (2) that stem cell products from 69% of patients have higher than this “safe” MRD level, and (3) that ET-18-OCH3 and hyperthermia may be used to purge products in part of these patients.